menu
    • menu
    [{"orgOrder":0,"company":"Intersect ENT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Intersect ENT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intersect ENT \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Intersect ENT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intersect ENT \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Intersect ENT","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Implant","sponsorNew":"Intersect ENT \/ Medtronic Plc","highestDevelopmentStatusID":"15","companyTruncated":"Intersect ENT \/ Medtronic Plc"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Intersect ENT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intersect ENT \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Intersect ENT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intersect ENT \/ Undisclosed"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Intersect ENT","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Intersect ENT \/ Medtronic Plc","highestDevelopmentStatusID":"15","companyTruncated":"Intersect ENT \/ Medtronic Plc"}]

    Find Clinical Drug Pipeline Developments & Deals by Intersect ENT

    Menu

    Intersect ENT

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved FDF

                            Sponsor : Medtronic Plc

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Medtronic Completes Acquisition of Intersect ENT

                            Details : Medtronic has acquired Intersect ENT's PROPEL™ and SINUVA™ (mometasone furoate) sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility.

                            Product Name : Propel

                            Product Type : Steroid

                            Upfront Cash : $1,100.0 million

                            May 13, 2022

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved FDF

                            Sponsor : Medtronic Plc

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved FDF

                            Sponsor : Medtronic Plc

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Medtronic to Acquire Intersect ENT

                            Details : Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing.

                            Product Name : Propel

                            Product Type : Steroid

                            Upfront Cash : $1,100.0 million

                            August 06, 2021

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved FDF

                            Sponsor : Medtronic Plc

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Intersect ENT

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Intersect ENT

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps ...

                            Details : Mometasone Furoate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sinusitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            November 30, 2017

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps

                            Details : Mometasone Furoate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sinusitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            November 14, 2014

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Performance of the Steroid-Releasing S8 Sinus Implant

                            Details : Mometasone Furoate is a Steroid drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sinusitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            July 10, 2013

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Intersect ENT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps

                            Details : Mometasone Furoate is a Steroid drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Sinusitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            November 26, 2012

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth